These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 16365288)

  • 1. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
    Lu X; Levine R; Tong W; Wernig G; Pikman Y; Zarnegar S; Gilliland DG; Lodish H
    Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18962-7. PubMed ID: 16365288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.
    Tefferi A; Gilliland DG
    Mayo Clin Proc; 2005 Jul; 80(7):947-58. PubMed ID: 16007902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
    Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
    Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.
    Lu X; Huang LJ; Lodish HF
    J Biol Chem; 2008 Feb; 283(9):5258-66. PubMed ID: 18158285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
    Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
    Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2, the JAK2 V617F mutant and cytokine receptors.
    Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
    Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-2 mutations and their relevance to myeloproliferative disease.
    Levine RL; Gilliland DG
    Curr Opin Hematol; 2007 Jan; 14(1):43-7. PubMed ID: 17133099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
    Levine RL; Wernig G
    Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
    Levine RL; Loriaux M; Huntly BJ; Loh ML; Beran M; Stoffregen E; Berger R; Clark JJ; Willis SG; Nguyen KT; Flores NJ; Estey E; Gattermann N; Armstrong S; Look AT; Griffin JD; Bernard OA; Heinrich MC; Gilliland DG; Druker B; Deininger MW
    Blood; 2005 Nov; 106(10):3377-9. PubMed ID: 16081687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
    Yao H; Ma Y; Hong Z; Zhao L; Monaghan SA; Hu MC; Huang LJ
    Leukemia; 2017 Oct; 31(10):2122-2131. PubMed ID: 28057939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
    Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
    Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated Jak2 with the V617F point mutation promotes G1/S phase transition.
    Walz C; Crowley BJ; Hudon HE; Gramlich JL; Neuberg DS; Podar K; Griffin JD; Sattler M
    J Biol Chem; 2006 Jun; 281(26):18177-83. PubMed ID: 16632470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
    Quentmeier H; Geffers R; Jost E; Macleod RA; Nagel S; Röhrs S; Romani J; Scherr M; Zaborski M; Drexler HG
    Leukemia; 2008 Dec; 22(12):2169-75. PubMed ID: 18769447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.